CAR T-cell therapy in Spain — get 3 personalized clinic matches
Bookimed lists 2 CAR t-cell therapy clinics in Spain, in Barcelona and Pamplona, including JCI-accredited clinics. These clinics are rated 4.7/5 in 504 verified patient reviews on Bookimed.
Medically reviewed by
Fahad Mawlood
How it works
How Much Does CAR T-cell therapy Cost in Spain?
CAR T-cell therapy in Spain typically costs from $380,000 to $520,000. Prices primarily depend on whether the treatment uses commercial products or hospital-developed academic protocols. Patients save around 21% compared to the US, where this procedure costs $480,000 on average. Quotes in Spain usually include T-cell collection, genetic engineering, chemotherapy, and a 20-30 day inpatient stay for monitoring.
- Commercial drug therapy: $380,000 to $520,000 for approved products like Kymriah and Yescarta.
- Hospital-developed protocols: Often 70-75% cheaper than commercial options through specialized European "Hospital Exemption" programs.
- Clinical trials: Some centers like Quironsalud Madrid offer potential cost reductions through active oncology trials.
- Location factors: Major medical hubs for this therapy include Barcelona, Madrid, and Pamplona.
Bookimed Expert Insight: Spain offers exceptional value because private centers like Centro Médico Teknon and Clinica Universidad de Navarra are JCI-accredited. Navigating these institutions is smart. Clinica Universidad de Navarra has a 74% bone sarcoma cure rate. While commercial drugs remain expensive, Spanish hospitals are pioneers in low-cost academic CAR T-cell manufacturing. SJD Barcelona Children's Hospital is a top 3 European pediatric center. It is ideal for families seeking specialized pediatric hematologists like Dr. Susana Rives Sola.
| Turkey | Austria | Spain | |
|---|---|---|---|
| CAR T-cell therapy | from $150,000 | ≈ $280,000 | from $380,000 |
| CAR-T for Pediatric ALL | ≈ $140,000 | ≈ $290,000 | ≈ $240,000 |
| CAR-T for Multiple Myeloma | ≈ $140,000 | ≈ $330,000 | ≈ $185,000 |
| CAR-T for DLBCL | ≈ $140,000 | ≈ $290,000 | ≈ $185,000 |
Discover the Best CAR T-cell therapy Clinics in Spain: 5 Verified Options and Prices
Centro Médico Teknon
Francesc Cobo Valien
CAR T-cell therapy Overview in Spain
- CAR T-cell therapy - from $380,000This therapy modifies patient"s cells to combat cancer, merging immunology and genetics. It"s precise, powerful, potentially one-off treatment.
Day 1
- Arrive at the airport.
- Enjoy the provided transfer to the clinic.
- Meet your language assistant if needed.
Day 2 - Day 3
- Undergo medical examination by a specialist.
- Receive a consultation with a hematologist.
- Undertake necessary tests (blood test, biopsy).
- If required, pre-operative procedures will be performed.
Day 4
- Start the CAR T-cell therapy process.
- Your T-cells will be collected and modified.
- This process lasts for about 2-3 hours.
- Local anesthesia is typically used.
Day 5 - Day 12
- Your modified T-cells are grown in the lab.
- No direct actions are required from you.
Day 13
- Receive your modified T-cells back via infusion.
- The infusion process lasts for about 1 hour.
Day 14 - Day 20
- Stay in the clinic for observation.
- Monitor your response to the therapy.
Week 3 - Week 4
- Continue to monitor your health condition.
- Consult with medical professionals regularly.
Week 5 onwards
- Rehabilitation begins.
- Resume work and moderate activities after 6 weeks.
- Return to intense activities like sports after 8 weeks.
- Expect to see the final result after 3 months.
Please note that each case is individual. This timeline may vary based on your personal health condition and the specifics of your treatment plan.
What patients like:
- Cost. The CAR T-cell therapy cost in Spain ranges from $380,000 to $520,000.
- Doctor’s professionalism. Spanish doctors are known for their high level of expertise. They possess international certificates and are members of reputable organizations.
- Service level. Patients enjoy the high-quality service in Spain. The staff's attentiveness and care make the experience comfortable.
- CAR T-cell therapy efficacy. The therapy has demonstrated high success rates, making it a preferred choice for many patients.
- Logistics. The process of receiving therapy is straightforward, with organized systems in place. This makes it less stressful for patients.
What patients don’t like:
- Waiting time. Despite the organized process, patients have expressed concerns over the waiting times for the therapy.
- Language barrier. Some patients have found the language barrier to be a challenge when communicating with the medical team.
- Aftercare. Patients have noted the need for better post-therapy care and follow-up services.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Susana Rives Sola
Specialist in bone marrow transplantation at SJD Barcelona Children's Hospital, focusing on pediatric hematology.
- Expertise in CAR T-cell therapy for children
- Works at one of Spain's leading pediatric hospitals
- Dedicated to advanced treatments for hematological conditions
Francesc Cobo Valien
Dr. Francesc Cobo Valien specializes in oncohematology with a focus on lymphoma and leukemia, backed by extensive research and prestigious awards.
- Graduated from the University of Barcelona in 1990
- Specialized in oncohematology at Hospital Clínic de Barcelona
- Recipient of multiple research grants and awards
- Expert in CAR T-cell therapy for hematologic malignancies
Carmen Martínez Chamorro
Dr. Carmen Martínez Chamorro is the Deputy Head of Hematology at Quironsalud Madrid Hospital. She is an oncohematologist specializing in adult bone marrow transplants. Dr. Chamorro treats complex cases of leukemia, lymphoma, and myeloma. She received the National Prize for Research in Surgery during her medical studies.
- Expert in stem cell procedures and adult hematologic oncology.
- Authored over 20 medical articles on blood disorders and treatments.
- Participated in over 60 national and international medical conferences.
- Practices at Quironsalud Madrid, ranked among the World's Best Hospitals by Newsweek.
Blanca Lopez Ibor
Dr. Blanca Lopez Ibor leads the Hematology & Pediatric Oncology Unit at HM Hospitales, specializing in pediatric hematology oncology with over 31 years of experience.
- Trained at the University of Maryland as a pediatric oncologist and hematologist
- Head of two foundations helping children with severe health issues
- Member of prestigious organizations including ASH and SIOP
- Consultant for WHO and UNESCO
Reviews about Bookimed: Discover Patients' Insights
All reviewsRelated Articles
CAR T-Cell Therapy Cost Effectiveness
Written by Anna Leonova
Share this content
Video Stories from Bookimed Patients
Anna Leonova
FAQ about CAR T-cell therapy in Spain
Who is eligible for CAR T-cell therapy in Spain?
Eligibility for CAR T-cell therapy in Spain is reserved for patients with relapsed or refractory hematological cancers who have exhausted standard treatments. Candidates typically include those with diffuse large B-cell lymphoma, B-cell acute lymphoblastic leukemia, or multiple myeloma after failing two or more therapy lines.
- Clinical indications: Patients must have specific lymphoma, leukemia, or myeloma diagnoses.
- Treatment history: Therapy is usually a second or third-line option after standard failures.
- Health status: Candidates require adequate organ function and a stable ECOG performance score.
- Authorized centers: Treatment occurs only at designated CSUR hubs in Barcelona, Madrid, or Pamplona.
Bookimed Expert Insight: Spain stands out for its academic CAR T-cell programs like ARI-0001, which are developed within public hospitals under hospital exemption rules. This allows centers like SJD Barcelona Children’s Hospital to offer cutting-edge cellular therapy variations that may not be available elsewhere, providing a critical alternative for pediatric patients.
Patient Consensus: Patients emphasize the importance of early consultation with a cellular therapist, as T-cell apheresis capacity often becomes a bottleneck for accessing timely care.
How effective is CAR T-cell therapy in Spanish clinics?
CAR T-cell therapy in Spain is highly effective, with remission rates reaching 84% to 87% for specific leukemia types. Spanish clinics lead in academic CAR-T development, offering outcomes comparable to commercial products while maintaining a high 12-month survival rate of approximately 80%.
- Remission rates: ARI-0001 therapy achieves 87% complete remission within three months.
- Survival outcomes: Specialized clinics report a 12-month overall survival rate of 80%.
- Treatment safety: Severe cytokine release syndrome occurs in only 12% of patients.
- Clinical availability: Over 7 clinics in Spain now administer 7 different CAR-T products.
Bookimed Expert Insight: Spain’s leadership in academic CAR-T therapy, such as the ARI-0001 protocol at Barcelona centers, provides a significant accessibility advantage. While commercial CAR-T can cost $520,000, Spain's academic versions offer a high-efficacy alternative often unavailable in other European medical hubs.
Patient Consensus: Patients value how Spanish university clinics provide CAR-T as a standard treatment. Those with advanced lymphoma specifically seek out Barcelona centers for specialized CD30 CAR-T trials.
Is CAR T-cell therapy available in Spain?
CAR T-cell therapy is widely available in Spain through advanced clinical trials and approved hospital-developed programs like ARI-0001. Leading facilities in Barcelona, Madrid, and Pamplona provide these cellular immunotherapies for hematologic malignancies including leukemia, lymphoma, and multiple myeloma.
- Treatment availability: Clinics offer CD30, ARI, and Anito-cell therapies for relapsed blood cancers.
- Leading institutions: JCI-accredited centers like Teknon and SJD Barcelona Children’s Hospital lead research.
- Regulatory oversight: The Spanish Agency of Medicines and Medical Devices (AEMPS) authorizes all academic protocols.
- Cost structure: Therapy in Spain ranges from $380,000 to $520,000.
Bookimed Expert Insight: Spain’s unique hospital exemption pathway allows academic centers to develop their own CAR-T versions legally. This leads to significantly lower costs than US commercial drugs. While the US average is $480,000, choosing Spanish academic programs can save you approximately 21% while maintaining high safety standards.
Patient Consensus: Patients value Spain as an affordable alternative to US costs, especially for experimental treatments. Many emphasize checking clinical trial eligibility early, particularly for late-relapse multiple myeloma therapy.
How long does the CAR T-cell process take?
The total CAR T-cell process in Spain typically takes 6 to 8 weeks from enrollment to infusion. While the actual cell infusion takes under 1 hour, the timeline includes leukapheresis, genetic engineering, and mandatory 30-day post-treatment monitoring to manage potential side effects.
- Evaluation period: Doctors confirm eligibility and cancer type over 5 to 7 days.
- Cell collection: Leukapheresis harvesting T-cells from the blood takes 3 to 4 hours.
- Lab manufacturing: Genetic modification and cell expansion require 2 to 3 weeks.
- Lymphodepletion phase: Chemotherapy prepares the body for new cells over 3 days.
- Clinical monitoring: Patients stay near JCI-accredited facilities for roughly 30 days post-infusion.
Bookimed Expert Insight: Spain offers a unique dual-track for timelines. While standard-of-care manufacturing is fixed, clinics like Quironsalud Madrid provide clinical trial access. These experimental protocols sometimes offer faster enrollment but require specialized pediatric hematologists like those at SJD Barcelona.
Patient Consensus: Patients emphasize that waiting for lab results is the most stressful phase. Many suggest preparing for a full 2-month stay in Spain to ensure safe recovery.
Where can I receive CAR T-cell therapy in Spain?
Spain offers CAR T-cell therapy at JCI-accredited centers in Barcelona and Madrid, specializing in advanced cellular immunotherapy for leukemia and lymphoma. Leading facilities include Centro Médico Teknon and Hospital Clínic de Barcelona, which pioneered academic CAR-T protocols like ARI-0001 for adult and pediatric oncology patients.
- Specialized oncology centers: Centro Médico Teknon and SJD Barcelona Children’s Hospital provide pediatric and adult care.
- Expert hematology units: Doctors at HM Montepríncipe and Teknon have over 20 years of immunotherapy experience.
- Advanced research access: Quironsalud Madrid offers clinical trials for patients seeking experimental third-generation CAR-T therapies.
- Quality certifications: Clinics like Hospital Ruber Internacional maintain JCI, ISO 9001, and ISO 14001 standards.
Bookimed Expert Insight: Spain is a global leader in academic CAR-T development, not just commercial pharmaceutical versions. Data shows clinics like SJD Barcelona Children’s Hospital serve 450,000 patients annually and participate in groundbreaking trials. For patients, this often means access to innovative third-generation CAR-T (Ainto-cell) which aims to reduce neurotoxicity risks.
Patient Consensus: Patients emphasize checking clinical trial eligibility for specific conditions like CD30 lymphoma or multiple myeloma. They focus on the high success rates in Spanish studies, noting complete remission in 60% of experimental cases.
Can a non-resident receive CAR T-cell therapy in Spain?
Non-residents can receive CAR T-cell therapy in Spain through the private healthcare sector or clinical research pathways. International patients typically access this immunotherapy at designated centers regulated by the Spanish Agency of Medicines and Medical Devices, often by utilizing hospital exemption rules for in-hospital cell manufacturing.
- Available facilities: Approximately 14 specialized centers like Clinica Universidad de Navarra provide CAR-T.
- Eligible conditions: Doctors treat specific relapsed or refractory blood cancers, including leukemias and lymphomas.
- Surgeon expertise: Specialists like Dr. Francesc Cobo Valien have over 25 years of hematology experience.
- Treatment range: Options include commercial products, biological therapies, and clinical trial-based research protocols.
Bookimed Expert Insight: Spain is a global leader in academic CAR-T development through the hospital exemption pathway. This allows clinics to produce cellular therapies on-site rather than relying strictly on pharmaceutical manufacturers. For patients, this creates more opportunities to join innovative clinical trials at centers like Quironsalud Madrid or SJD Barcelona.
Patient Consensus: Patients often find that clinical trials are the most viable path for long-term care. Navigating medical immigration and visa logistics remains the primary challenge for those traveling from outside the European Union.